Toronto General Hospital
Toronto Western Hospital
Princess Margaret 20 Hospital 04 RESEARCH REPORT ABOUT RESEARCH
ABOUT RESEARCH AT UNIVERSITY HEALTH NETWORK 20 Total Number of Researchers 468 Senior Scientists 160
Scientists 54
Affiliate Scientists 47 04 CSRC Members 207 Contents Investing in Future Health - From the President & CEO 1 Total Number of Trainees 770 Strong Funding Based on Strong Science - From the VP 2 Fellows 397 The Year in Review 4 Ontario Cancer Institute 6 PhD Students 81 Toronto General Research Institute 8 Toronto Western Research Institute 10 Other Graduate Students 292 Features 12 Breakthroughs 18 Staff 996 Funding 30 Committees/Services 32 Research Space 480,000 sq ft Analysis of Research Activity 35 Publications 1293 Endowed Chairs 36 International Research Advisory Board 37 Total Research Funding $155,976,000
RESEARCH REPORT 2004 FROM THE PRESIDENT & CEO
Investing in Future Health
Tom Closson
niversity Health Network in 2004 is an amazing commitment of our researchers and research staff and their place to be, and UHN Research is one of the things partners in the government, community and private sector. U that makes it so. From the research funding flowing from federal, provincial Patient care, education, and research are all highly intercon- and international agencies, to the community volunteers who nected. UHN attracts some of the best clinicians—because it sit on our boards and committees, to the enormously dedicated offers the opportunity to combine clinical practice with research. work of the three UHN Foundations—the Arthritis & UHN attracts many patients from across Ontario due to high Autoimmunity Research Centre Foundation, the Princess standards of care and the opportunity to participate in ground- Margaret Hospital Foundation and the Toronto General & breaking clinical research—all because of the thriving Western Hospital Foundation—we owe an enormous debt research community here. of thanks to many groups for their ongoing support. The UHN strategic plan, Strategic Directions 2011, outlines An investment in biomedical research is an investment ambitious targets for all of us at UHN. As this Research Report in future health. UHN has much to be proud of in this area. documents, Research is making great strides towards these Please read on to learn more. targets. This year saw new buildings, new institutes, new Tom Closson initiatives and new partnership ventures in Research. President and Chief Executive Officer None of this would be possible without the hard work and University Health Network
UNIVERSITY HEALTH NETWORK 1 FROM THE VICE PRESIDENT
Strong Funding Based on Strong Science
Christopher J. Paige, PhD
esearch has had an amazing year in 2003/04. impressive. As a hospital-based This year for the first time our research budget This year for the research institute, our programs R topped $150M, with strong support from provincial first time our of inquiry span the spectrum from and national agencies including an all-time high of $20.5M from research budget fundamental understanding of the national Canadian Institutes of Health Research, nearly topped $150M molecules and cells to mission- $10M from the National Cancer Institute of Canada and $6M oriented, disease-specific clinical from the new Ontario Cancer Research Network. These figures research. Our discoveries reflect this diversity: the first approved demonstrate yet again the scientific excellence of our scientists treatment for SARS; a multi-drug protocol that extends the lives and the members of their research programs. They also show of lung cancer patients; identification of a leukemia stem cell; how reliant we are on a strong research funding environment discovery of a new mechanism that controls brain cell death to fuel research at UHN and how this support is key in realizing during stroke; and a novel molecular switch that controls the the research achievements that generate advances in patient process of inflammation. Breakthroughs like these hold the care at Canada’s largest hospital. promise of improving the lives of our patients today or in the Topping off the year came the announcement in March that not too distant future. our researchers won $36.4M in infrastructure funding from federal UHN’s achievements rest on the achievements of our and provincial sources to launch three new centres—the Advanced individual investigators. UHN researchers have received Medical Discovery Institute, the Centre for Research in Immune many individual honours this year, achieving global Tolerance in Transplantation, and the STTARR Centre in radia- and national renown. Some of these include: tion medicine. We are tremendously proud of this achievement ■ The Paul Ehrlich and Ludwig Darmstaedter Prize, the highest and it will prove critical in developing our research capacity in prize awarded in Germany in the field of medicine, awarded key areas in the next few years. to Dr. Tak Mak In 2003/04 UHN’s list of scientific accomplishments was ■ The appointments of Dr. Peter St George-Hyslop as Fellow
2 RESEARCH REPORT 2004 FROM THE VICE PRESIDENT
of the Royal Society and Dr. John Dick as a Fellow UHN’s strengths in basic, transla- of the Royal Society of Canada UHN Global tional and clinical research to accel- ■ The naming of Drs. Jim Woodgett and Peter St George- Ventures is a new erate innovations further down the Hyslop as International Research Scholars by the R&D interface that development pipeline and capture Howard Hughes Medical Institute will capitalize on more value for UHN’s research ■ The appointments of Drs. Cheryl Arrowsmith, Dan Drucker UHN’s strengths investment. A third new venture and Mitsu Ikura as Tier I Canada Research Chairs and owes a great deal to the Princess Dr. Peter Cheung as a Tier II Canada Research Chair Margaret Hospital Foundation, which was a driving force ■ The Society for Thoracic Surgeons’ Earl Bakken award for behind its development. The Institute for Breast Cancer lifetime scientific achievement, awarded to Dr. Richard Weisel Research, opened this year under the leadership of Dr. Tak ■ Honorary degrees from the University of Toronto awarded Mak, is an exciting development in the field and will no doubt to Drs. Jim Till and Ernest McCulloch, who were also this be the focus of many future pieces in this report. year elected to the Canadian Medical Hall of Fame All told, the year 2003/04 was an important year in the growth ■ Dr. Tony Lang, who received the American Academy of UHN’s research enterprise. And, as in previous years, I’d like of Neurology’s Movement Disorders Research Award to close by offering my thanks and congratulations to all who Finally, this year saw progress in three significant new contributed to UHN Research’s success in 2003/04: our scien- ventures. The Toronto Medical Discovery Tower, critical for tists and clinician-scientists, our technical and support staff, our increasing research space capacity, neared completion this students and fellows, our colleagues in the Toronto Academic year and we are currently awaiting handover of the shell Health Sciences Network, and, most especially, our Foundations. space for UHN’s interior fit-out and occupancy in 2005. UHN Christopher J. Paige, PhD Global Ventures was launched this year under the leadership Vice President, Research of Dr. Brian Barber. This R&D interface will capitalize on University Health Network
UNIVERSITY HEALTH NETWORK 3 HIGHLIGHTS
The Year in Review
DECEMBER 2003
The second meeting of the UHN International Research Advisory Board brings together four internationally-recognized scientists in high-impact areas to meet with various UHN constituencies including researchers, platform leaders, medical program leaders, foundations and hospital and research leadership.
JANUARY 2004
The UHN Platform planning process, Phase II of The Future Project, launches. Led by Platform Chairs, the nine-month process aims NOVEMBER 2003 to define visions and new The second annual UHN tactical plans for the four Research Day held at UHN Platforms: Genes, a Toronto hotel provides Proteins & People, Health a chance for researchers Informatics, Medical to mingle and learn about Technology Innovation, and projects and findings from Regenerative Medicine. UHN colleagues. Keynote speaker was Dr. Catherine MARCH 2004 Verfaille, Director of the Stem Cell Institute at the The Research strategic plan University of Minnesota. entitled The Future Project is Also announced at the event approved by the UHN Board was the recipient of the of Trustees. inaugural UHN Inventor of the Year award: Dr. Kevin Three teams of UHN Kain, honoured for his work researchers celebrate the in new malaria treatments. announcement of awards totaling nearly $18.2M from the Canada Foundation
4 RESEARCH REPORT 2004 HIGHLIGHTS
for Innovation to build new infrastructure to study the mechanisms of cancer, radia- tion medicine and immune tolerance. These awards were later matched by the Ontario government (Ministry of Economic Development and Trade/Ontario Innovation Trust), bringing funding to a total of $36.4M.
APRIL 2004
Dr. Peter St George-Hyslop becomes Director of the Toronto Western Research Institute. His research in determining the genetic and molecular processes underlying neurodegenerative diseases, particularly Alzheimer’s disease, has had a major impact in the field and has been recognized by many national and interna- tional awards.
MAY 2004 JUNE 2004
▲ Dr. Brian Barber is recruited A significant milestone is to helm UHN Global Ventures, reached as the new Toronto Integrating basic, translational a new initative promoting com- Medical Discovery Tower is and clinical research, the mercialization and partnership topped off in a short ceremony new $125M Institute for Breast with UHN Research on an held 15 floors above ground. Cancer Research launches international level. UHN is eagerly anticipating the on June 2, 2004. Director hand-over of the building for Dr. Tak Mak begins assembling fit-out starting October 2004. Canada’s first scientific team to develop new improved drugs and therapies to conquer breast cancer.
UNIVERSITY HEALTH NETWORK 5 OCI
Ontario Cancer Institute Princess Margaret Hospital
AFFILIATE SCIENTIST STAFF AND STUDENTS Ritvo, Paul
Total Number of Researchers 137 Experimental Therapeutics Senior Scientists 48 SENIOR SCIENTISTS Scientists 17 Hedley, David Affiliate Scientists 4 Hill, Richard CSRC Members 69 Hunt, John Khokha, Rama Total Number of Trainees 350 Liu, Fei-Fei Fellows 164 Moore, Malcolm PhD Students 45 Rauth, Michael Rottapel, Robert Other Graduate Students 141 Stewart, Keith Tannock, Ian Staff 397 Whitmore, Gordon Woodgett, Jim Cancer Penn, Linda Informatics Squire, Jeremy SCIENTISTS SENIOR SCIENTISTS Tsao, Ming Bristow, Robert Asa, Sylvia Cheung, Peter Research Space 222,000 sq ft Gallie, Brenda SCIENTISTS Done, Susan Hakem, Razq Koch, Anne Publications 370 SCIENTIST Harrington, Lea Medin, Jeffrey Total External Funding $55,000,000 Jurisica, Igor Schimmer, Aaron Stambolic, Vuk Vaziri, Homayoun Tillier, Elisabeth Cell & Wells, Richard Vallis, Katherine Molecular Yeh, Wen-Chen Biology AFFILIATE SCIENTIST SENIOR SCIENTISTS AFFILIATE SCIENTISTS Leong, Weh-Liang Barber, Dwayne Bradley, Grace Benchimol, Sam Kamel-Reid, Suzanne Medical Physics Iscove, Norman SENIOR SCIENTISTS Lepock, James Epidemiology, Jaffray, David Mak, Tak Statistics & Sherar, Michael Manoukian, Armen Behaviour Vitkin, Alex McCulloch, Ernest SENIOR SCIENTISTS Wilson, Brian Messner, Hans Boyd, Norman Miller, Richard Cunningham, Alastair SCIENTISTS OCI includes the Advanced Medical Minden, Mark Minkin, Salomon Lilge, Lothar Discovery Institute and the Institute Ohashi, Pam Till, James Siewerdsen, Jeff for Breast Cancer Research Paige, Christopher Tritchler, David
6 RESEARCH REPORT 2004 OCI
Molecular & Gryfe, Robert Warr, David Structural Hodgson, David Wells, Woodrow RESEARCH Biology Howell, Doris Wong, Rebecca COUNCIL SENIOR SCIENTISTS Irish, Jonathan Zimmermann, Camilla Arrowsmith, Cheryl Kane, Gabrielle DIRECTOR Chakrabartty, Avi Kim, John NB-where members have more Christopher J. Paige Edwards, Aled Knox, Jennifer than one affiliation, only CANCER INFORMATICS Gariépy, Jean Krzyzanowska, Monika one affiliation is indicated Brenda Gallie Ikura, Mitsu Laperriere, Norm Ottensmeyer, Peter Leighl, Natasha CELL & Pai, Emil Levin, Wildred MOLECULAR Privé, Gilbert Lipa, Joan BIOLOGY Richardson, Christopher Lipton, Jefferey Sam Benchimol Rose, David Manchul, Lee EPIDEMIOLOGY, Mason, Warren STATISTICS & Clinical Studies McCready, David BEHAVIOUR Resource Centre McLean, Michael Norman Boyd MEMBERS Mikhael, Joseph Bayley, Andrew Milosevic, Michael EXPERIMENTAL Bell, Robert Neligan, Peter THERAPEUTICS Bezjak, Andrea O'Sullivan, Brian Jim Woodgett Brandwein, Joseph Oza, Amit MEDICAL PHYSICS Brierley, James Paul, Narinder Brian Wilson Brown, Dale Payne, David Catton, Charles Pierre, Andrew MOLECULAR & Catton, Pam Quirt, Ian STRUCTURAL Chen, Christine Reece, Donna BIOLOGY Chen, Eric Ringash, Jolie Emil Pai Chetty, Runjan Rosen, Barry CLINICAL Crook, Juanita Rotstein, Lorne REPRESENTATION Crump, Michael Shaw, Patricia Armand Keating Cummings, Bernard Shepherd, Frances Mary Gospodarowicz Darling, Gail Simpson, Rand Jonathan Irish Dawson, Laura Siu, Lillian Easson, Alexandra Sturgeon, Jeremy SITE Elliott, Mary Sun, Alexander REPRESENTATION Evans, Andrew Swallow, Carol Robert Bell Feld, Ronald Tkachuk, Doug CLINICAL STUDIES Fleshner, Neil Trachtenberg, John RESOURCE CENTRE Fyles, Anthony Trudel, Suzanne Robert Bell Gallinger, Steve Tsang, Richard Gospodarowicz, Mary Waldron, John Greig, Paul Warde, Padraig
UNIVERSITY HEALTH NETWORK 7 T GRI
Toronto General Research Institute Toronto General Hospital
Langille, Lowell STAFF AND STUDENTS Levy, Gary Total Number of Researchers 198 Liu, Mingyao Senior Scientists 70 Phillips, James Rotstein, Ori Scientists 25 Rubin, Barry Affiliate Scientists 29 Schuh, Andre CSRC Members 75 Whiteside, Catherine Zacksenhaus, Eldad Total Number of Trainees 291 Zhang, Li Fellows 159 PhD Students 25 SCIENTISTS Other Graduate Students 107 Belsham, Denise Cattral, Mark Husain, Mansoor Staff 422 Irwin, David Jin, Tianru Behavioural Heslegrave, Ron Kapus, Andras Sciences & Health Hodges, Brian Trinh, Denny Waddell, Thomas SENIOR SCIENTISTS Irvine, Jane Devins, Gerald Katz, Mark AFFILIATE SCIENTISTS Flint, Alastair McVey, Gail Branch, Donald Research Space 153,000 sq ft Kaplan, Allan Reid, Graham Clark, David Publications 596 Katz, Joel Ritvo, Paul Cole, Edward Olmsted, Marion Robinson, Gail Total External Funding $45,700,000 Ojha, Matadial Rodin, Gary Styra, Rima Wilson, Gregory Stewart, Donna Woodside, Blake
Clinical Decision- SCIENTISTS Cell & Molecular Making & Health Carter, Jacqueline Biology Care Esplen, Mary Jane SENIOR SCIENTISTS SENIOR SCIENTISTS Jones, Jennifer Backx, Peter Bombardier, Claire Nolan, Robert Berger, Stuart Eysenbach, Gunther Regehr, Glenn Cybulsky, Myron Dick, John Jadad, Alex Naglie, Gary AFFILIATE SCIENTISTS Drucker, Daniel Abbey, Susan Elsholtz, Harry SCIENTISTS Baker, Brian Fantus, George Alibhai, Shabbir Davis, Caroline Fish, Eleanor Krahn, Murray de Groot, Janet Gorczynski, Reginald Maetzel, Andreas Gagliese, Lucia Gotlieb, Avrum Urbach, David Grace, Sherry Grant, David Wilson, Kumanan Hamstra, Stanley Johnston, Wayne
8 RESEARCH REPORT 2004 T GRI
AFFILIATE SCIENTISTS Mickle, Donald Brister, Stephanie McLaughlin, Peter Goel, Vivek Stewart, Keith Cameron, Douglas McRae, Karen RESEARCH Lok, Charmaine Weisel, Richard Cardella, Carl Merchant, Naeem COUNCIL Tomlinson, George Chan, Charles Neligan, Peter SCIENTISTS Chan, Christopher O'Malley, Martin DIRECTOR Clinical Rao, Vivek Chauhan, Vijay Parker, John Keith Stewart Investigation Volchuk, Allen Colman, Jack Rajan, Dheeraj & Human Physiology Yau, Terrence Cooper, Richard Rakowski, Harry BEHAVIOURAL SENIOR SCIENTISTS Daly, Paul Ralph-Edwards, Anthony SCIENCES & HEALTH Allard, Johane AFFILIATE SCIENTISTS Darling, Gail Reznick, Richard Gary Rodin Bradley, Douglas McCart, Andrea David, Tirone Richardson, Robert CELL & MOLECULAR Cattran, Daniel McGilvray, Ian Djaiani, George Roberts, Heidi BIOLOGY Detsky, Allan Medin, Jeffrey Dzavik, Vladimir Ross, John Eleanor Fish Downar, Eugene Fedorko, Ludwik Ross, Heather Floras, John Genomic Medicine Fenton, Stanley Salit, Irving CLINICAL DECISION- MAKING & Goss, Paul SENIOR SCIENTISTS Fisher, Joseph Schwartz, Len HEALTH CARE Kucharczyk, Walter Cole, David Gallinger, Steve Seidelin, Peter Claire Bombardier Lewis, Gary Downey, Gregory Gardam, Michael Sherman, Morris Logan, Alexander George, Susan Girgrah, Nigel Singer, Lianne CLINICAL INVESTIGATION & Marshall, John Hogg, David Gold, Wayne Siu, Samuel HUMAN PHYSIOLOGY Miller, Judith Kain, Kevin Goldszmidt, Eric Slinger, Peter John Marshall Olivieri, Nancy MacDonald, Kelly Granton, John St George-Hyslop, Peter Phillipson, Eliot Pei, York Greig, Paul Sternbach, Yaron EXPERIMENTAL Steiner, George Siminovitch, Kathy Grigoriadis, Sophie Strauss, Sharon THERAPEUTICS Walmsley, Sharon Sole, Michael Harris, Louise Sutton, David David Kelvin Waxman, Menashe Herridge, Margaret Sweet, Joan GENOMIC MEDICINE Webb, Gary SCIENTISTS Humar, Atal Wilson, Stephanie Katherine Siminovitch Zamel, Noe Osborne, Lucy Ing, Douglas Wolman, Stephen Jassal, Vanita Yeo, Erik CLINICAL STUDIES SCIENTISTS AFFILIATE SCIENTISTS Jewett, Michael RESOURCE CENTRE NB-where members have more Cheung, Angela Boright, Andrew Johnston, Michael John Parker than one affiliation, only Reilly, Raymond Denomme, Greg Kachura, John one affiliation is indicated CLINICAL Wong, Florence Kapral, Moira REPRESENTATION Clinical Studies Karkouti, Keyvan Carl Cardella Karski, Jacek Experimental Resource Centre Christopher Feindel Therapeutics MEMBERS Kennedy, Sidney Gary Levy SENIOR SCIENTISTS Ali, Mohamed Keystone, Edward Keating, Armand Bacchus, Maria Lapinsky, Stephen SITE Kelvin, David Bargman, Joanne Lilly, Leslie REPRESENTATION Keshavjee, Shaf Beattie, Scott Lipa, Joan Janet Beed Li, Ren-Ke Borger, Michael Loke, Julian VP RESEARCH Lindsay, Thomas Bradley, John Manktelow, Ralph Christopher J. Paige Liu, Peter Bril, Vera McCluskey, Stuart
UNIVERSITY HEALTH NETWORK 9 TWRI
Toronto Western Research Institute Toronto Western Hospital
Bremner, Roderick STAFF AND STUDENTS Broussard, Dianne Cardella, Carl
Total Number of Researchers 134 Carlen, Peter Eubanks, James Senior Scientists 43 Fehlings, Michael Scientists 12 Inman, Robert Affiliate Scientists 15 Jongstra, Jan CSRC Members 64 Mills, Linda Nag, Sukriti Total Number of Trainees 129 Schlichter, Lyanne Fellows 74 Skinner, Frances PhD Students 11 Stanley, Elise Tator, Charles Other Graduate Students 44 Tsui, Florence Tymianski, Michael Staff 177 Wither, Joan
Applied & SCIENTISTS SCIENTISTS Interventional Hutchison, William Jongstra-Bilen, Jenny Research Chen, Robert Monnier, Philippe SENIOR SCIENTISTS Hudson, Christopher Sugita, Shuzo Research Space 105,000 sq ft Brotchie, Jonathan Kucharczyk, Walter Wan, Qi Davis, Karen Roberts, Timothy Zhang, Liang Publications 394 De Nil, Luc Wong, Agnes Total External Funding $14,900,000 Diamant, Nicholas AFFILIATE SCIENTISTS Feindel, Christopher AFFILIATE SCIENTISTS El-Beheiry, Hossam El-Din Flanagan, John Dostrovsky, Jonathan Gallie, Brenda Hassouna, Magdy Eizenman, Moshe Lang, Anthony Ethier, Ross Outcomes & Lozano, Andres Guha, Abhijit Population Mailis, Angela Halliday, William Health McAndrews, Mary Pat Hamstra, Stanley SENIOR SCIENTISTS Mikulis, David Harvey, Patricia Badley, Elizabeth Saint-Cyr, Jean Irving, Elizabeth Carette, Simon Sandor, Paul Kayumov, Leonid Cassidy, David Shapiro, Colin Stephens, Robyn Fortin, Paul Sharpe, James Wilkinson, Frances Gladman, Dafna Steinbach, Martin Urowitz, Murray Trope, Graham Cell & Wallace, Christopher Molecular SCIENTISTS Biology Gignac, Monique SENIOR SCIENTISTS Mahomed, Nizar Barr, Cathy
10 RESEARCH REPORT 2004 TWRI
AFFILIATE SCIENTISTS Panisko, Daniel Tarlo, Susan Cott, Cheryl Parikh, Sagar Terbrugge, Karel RESEARCH Glazier, Richard Peng, Philip Tu, Karen COUNCIL Lineker, Sydney Radomski, Sidney Tumber, Paul
Rampersaud, Yoga Raja von Schroeder, Herbert DIRECTOR Clinical Studies Rootman, David Voon, Valerie Peter St George-Hyslop Resource Centre Rosen, Cheryl Wherrett, John MEMBERS Seyone, Chanth Willinsky, Robert APPLIED & INTERVENTIONAL Anastakis, Dimitri Shannon, Patrick Wong, David RESEARCH Bernstein, Mark Shaw, James Wong, Jean Andres Lozano Bookman, Arthur Silver, Frank Yogendran, Suntheralingam Buys, Yvonne Simons, Martin Yu, Eric Ho Cheung CELL & MOLECULAR Chan, Vincent Singer, Shaun BIOLOGY Chapman, Kenneth Slomovic, Allan NB-where members have more than one affiliation, Elise Stanley Chung, Frances St George-Hyslop, Peter only one affiliation is indicated Davey, Roderick Stanbrook, Matthew OUTCOMES & Del Campo, Martin Jose POPULATION HEALTH Devenyi, Robert Elizabeth Badley Epstein, Trina
Escallon, Jaime CLINICAL STUDIES Etlin, David RESOURCE CENTRE Evans, Michael Jenny Heathcote Farb, Richard CLINICAL Fung, Ken REPRESENTATION Gentili, Fred Michael Fehlings Graham, Brent Nizar Mahomed Hawa, Raed Martin Steinbach Heathcote, Jenny
Iwanochko, Mark SITE Lam, Robert REPRESENTATION Lam, Wai-Ching Catherine Zahn Manninen, Pirjo VP RESEARCH Massicotte, Eric Christopher J. Paige McCartney, Colin McGuire, Glenn McIntyre, Roger Melvin, Kenneth Miyasaki, Janis Montanera, Walter Moro, Elena Nasmith, James Oandasan, Ivy Ogilvie, Richard Ogilvie-Harris, Darrell
UNIVERSITY HEALTH NETWORK 11 NEW TOWER
Toronto Medical Discovery Tower at MaRS
This year the new Toronto Medical Discovery Tower continued to take shape at the corner of College and Elizabeth Streets
he new Toronto Medical Discovery Tower, first phase the McEwen Regenerative Medicine Centre for gene, cell and of the Medical and Related Sciences (MaRS) tissue therapy...a satellite of the McLaughlin Centre for Molecular T development, is a 400,000 sq ft, 15 floor building Medicine including programs in global health and stem cell currently under construction. research...an imaging program for testing new imaging modalities on small to large animal models...and a number of smaller initia- Allowing Expansion of UHN Research Programs tives proposed by research groups. UHN researchers will occupy nine floors when completed. “This new space will be a tremendous boon to UHN Research,” notes State-of-the-Art Construction for Research Dr. Christopher Paige, Vice President, Research. “It will allow us The tower has been designed as a fully integrated research to expand critical programs and launch new programs from the facility with significant flexibility on a floor by floor basis. ground up.” With the building quickly taking shape, occupancy Unique features include 100% fresh air, independent air handlers is on track for September 2005. on each floor, a highly stable structure (minimal vibrational/ UHN programs under discussion for creation in TMDT include sway impact), a central reverse osmosis water system, and a new drug discovery program incorporating medicinal specialty exhaust risers. chemistry and structural biology...a research program UHN Research will The base building construction for the Toronto in infectious diseases/immune system research... occupy nine floors Medical Discovery Tower is expected to be complete a convergence centre bringing together a team of in this new state- by the end of 2004, with interior fit-out already engineers, physicists, biologists and clinical researchers of-the-art building underway. TMDT will be ready for full occupation to work on multi-disciplinary problems...a home for by September 2005.
12 RESEARCH REPORT 2004 NEW TOWER
TMDT MILESTONES
BASE BUILDING
May 04 Oct 04 Jan 05 Concrete Glass Base building structure enclosure systems completed completed completed
INTERIOR FINISH
Oct 03 Jan 04 Aug 04 Dec 04 Sept 05 Concept Schematic Interior Detail Full occupancy design design construction design for UHN completed completed initiated completed Research
TMDT STATISTICS
■ Workers on site each day 140 ■ Exterior glass 15,600 m2 ■ Volume of excavated earth 29,750 m3 ■ Window frames 2,500 ■ Concrete poured 20,000 m3 ■ Doors and frames 295 ■ Structural steel 179,000 kg ■ Elevators 9 ■ Reinforcing steel 2,770,000 kg ■ Historical bricks salvaged 50,000 ■ Indiana limestone (exterior) 11,800 ft2 ■ New trees planted 43
UNIVERSITY HEALTH NETWORK 13 NEW INSTITUTE
New Institute for Breast Cancer Research Opens
A first in Canada, new institute will attack disease on basic, translational and clinical research fronts
une 2004 marked the launch of UHN’s newest research Within the past three to five years, these drugs have become initiative, the Institute for Breast Cancer Research. Fuelled available for many types of cancers—including leukemia and colon J by generous donor and Foundation support, led by one and stomach cancers. Based on the pioneering work done by of Canada’s top scientists, and including a stellar scientific team, Dr. Mak and others, new mechanistically-based treatments for the new program promises significant future breakthroughs against breast cancer are not far behind. a disease that strikes one in nine Canadian women. Scientific Leadership Making an Impact Dr. Mak is one of Canada’s most prolific researchers and is most “Advances in basic research have created a new opportunity ready famous for his 1984 landmark scientific paper on the cloning of the for translation into the clinic. Scientists now have the tools— T cell receptor genes, a key component of the human immune knowledge of the molecular and genetic factors in the system. He is a Senior Scientist with the hospital’s development of breast cancer—to make an impact Mechanistically- research arm, the Ontario Cancer Institute, as well as on the treatment of breast cancer,” says Dr. Tak Mak, based drugs offer a University Professor with the University of Toronto, director of the new initiative. an Officer of the Order of Canada, and one of a the promise of Mechanistically-based drugs—drugs which offer the handful of Canadians elected a Foreign Associate better treatment promise of better treatment with fewer side effects— of the National Academy of Sciences (USA) and a are rapidly becoming a reality as scientists reveal new with fewer Fellow of the Royal Society. His international recogni- insights into the genetic and cellular mechanisms of side effects tion includes the King Faisal Prize for Medicine, the cancer development. Gairdner Foundation International Award, the Sloan
14 RESEARCH REPORT 2004 NEW INSTITUTE
Institute members Drs. Yeh, Harrington, Mak, Boyd and Ohashi.
Prize of the GM Cancer Foundation, and, most recently, Up to six investigators to be recruited in the coming months Germany’s top scientific award, the Paul Ehrlich and Ludwig will provide additional clinical and translational research expertise. Darmstaedter Prize. The new Institute was launched with a goal of raising a total of Dr. Mak’s studies of mice deficient in genes involved in tumori- $125M. Already, $60M is committed, with part of the money coming genesis, including MSH2, DPC-4, PTEN and the breast cancer from funds raised by thousands of walkers in the annual Weekend genes BRCA1 and BRCA2, have furthered our understanding of to End Breast Cancer event in Toronto held in September. cancer development. Using mutant mice that have been disrupted The Princess Margaret Hospital Foundation is pledging to raise in the genes encoding FADD, Apaf-1, TNFR1, and several TRAFs an additional $65M from private donors, corporations and other and caspases, he and his colleagues have dissected pathways of sources to fund the Institute. cellular survival and programmed cell death. ADVISORY BOARD OF THE Innovative Collaborations INSTITUTE FOR BREAST CANCER RESEARCH Also key to this program is its translational and clinical research Paul Alofs David McCready slant. The new initiative will bring together many types of cancer Robert Bell Christopher Paige researchers—scientists, clinicians and others—to conquer breast cancer. Already on board are noted epidemiologist Norman Boyd, Carole Grafstein Lionel Robins MD, DSc, FRCPC; Terry Fox Young Investigator Lea Harrington, Audrey Loeb Katherine Vallis PhD; recent AAAI Investigator Award winner Pam Ohashi, PhD; Tak Mak and noted investigator Dr. Wen-Chen Yeh, MD, PhD.
UNIVERSITY HEALTH NETWORK 15 DIRECTOR APPOINTMENT
Toronto Western Research Institute Welcomes New Director
World-renowned neurologist and molecular geneticist Dr. Peter St George-Hyslop appointed
his year UHN was pleased to has a strong tradition in neuroscience welcome Peter St George-Hyslop, research, and the Toronto community is T MD, as new Director of the also recognized internationally for research Toronto Western Research Institute. in this area.” Dr. St George-Hyslop’s pioneering Dr. St George-Hyslop received his MD genetics research into susceptibility and degree from the University of Ottawa prior neurodegeneration in Alzheimer’s disease to doing postgraduate training at Ottawa, has had a major impact, establishing him Toronto and Harvard. His first staff appoint- as an international authority in the field. ment was at Massachusetts General He has published more than 200 Hospital, and he returned to Toronto in papers in leading peer-reviewed journals, 1991 as Assistant Professor, Department and he has won numerous prestigious of Medicine (Neurology). awards, including two Howard Hughes Currently Director of the Memory International Scholar Awards Disorders Clinic at TWH, (1997 and 2002) and a A leader in the Dr. St George-Hyslop is Distinguished Scientist Award field of Alzheimer’s also Director of the from the Canadian Institutes of disease research, Centre for Research in Health Research in 2001. Most Dr. St George- Neurodegenerative recently he was appointed to Hyslop has Diseases and Professor the Royal Society. published more in the Department of “I am excited by the oppor- than 200 scientific Medicine at the University tunity to provide leadership of Toronto. He also speaks papers in his Dr. Peter St George-Hyslop, Director here,” says Dr. St George- extensively to public audiences of the Toronto Western Research Institute lifetime. Hyslop. “The research institute about Alzheimer’s disease.
16 RESEARCH REPORT 2004 STRATEGIC PLANNING
Strategic Planning in Research at UHN
Platform strategic planning process launched; new plans in progress
cientific breakthroughs occur biomedical research field and gauging new extensive consultation process involving daily. How can a research hospital opportunities for development. input from UHN investigators, Research S best position itself to be at the Councils and Platform Task Forces. This forefront of scientific and clinical change? Progress in 2003/04 process included discussion forums, focus This is the main question underlying This year marked the launch of The Future groups and the online survey Call for Ideas! strategic planning at UHN. Project Phase II. Its goal is to develop Beginning with the hospital-wide strate- detailed tactics for implementing the strate- Future Steps gic plan approved in 2001, and including gies detailed in Phase I. The draft plan will become available in late the draft research plan drafted in 2002 and A core of 12 Platform executives, aided 2004 for review and feedback by researchers finalized in 2004, UHN Research has been by Task Forces, led this process. From and research leadership as well as the UHN involved with scanning the horizons of the January to June, they embarked on an International Research Advisory Board.
UHN thanks the Platform Chairs and Task Forces for their efforts to date:
GENES, PROTEINS & Minden, Mark Gospodarowicz, Mary Irish, Jonathan Bell, Robert PEOPLE Monnier, Philippe Heathcote, Jenny Kapoor, Shitij Benchimol, Sam Penn, Linda (Chair) Schimmer, Aaron Jadad, Alex Kucharczyk, Walter Brotchie, Jonathan Bremner, Rod (Site Leader) Siminovitch, Katherine Levinson, Wendy Langille, Lowell Fehlings, Michael Kain, Kevin (Site Leader) Stanley, Elise Martino, Rosemary Levy, Gary Feindel, Christopher Arrowsmith, Cheryl Stewart, Keith McAndrews, Mary Pat Fish, Eleanor Barr, Cathy Woodgett, Jim MEDICAL Raghibizadeh, Sasan Kelvin, David Cheung, Peter TECHNOLOGY Ruda, Harry Levy, Gary Downey, Greg HEALTH INFORMATICS INNOVATION Sefton, Michael Stanley, Elise Fehlings, Michael Maetzel, Andreas (Chair) Davis, Karen (Chair) Siewerdsen, Jeffrey Woodgett, Jim Fish, Eleanor Miyasaki, Janis (Site Leader) Jaffray, David (Site Leader) terBrugge, Karel Floras, John Siu, Lillian (Site Leader) Rao, Vivek (Site Leader) Wilson, Brian Inman, Robert Bacchus, Maria Bell, Robert Jongstra, Jan Badley, Elizabeth Chan, Christopher REGENERATIVE Jurisica, Igor Bombardier, Claire Cybulsky, Myron MEDICINE Kaul, Rupert Borger, Michael Fehlings, Michael Waddell, Thomas (Chair) Keating, Armand Bournes, Debra Feindel, Chris Medin, Jeffrey (Site Leader) Lewis, Peter Crawford, Lindsey Husain, Mansoor Schlichter, Lyanne Mak, Tak Gallie, Brenda Inman, Robert (Site Leader)
UNIVERSITY HEALTH NETWORK 17 BREAKTHROUGHS
Breakthroughs Ontario Cancer Institute
The stories below showcase some of the many breakthroughs that occurred this year at UHN.
Breast Cancer: breast cancer returning by 44% in post- Many post-menopausal New Drug So Promising menopausal women. “Having ended the breast cancer survivors take That Trial Cut Short trial, we are now able to offer letrozole tamoxifen to ensure that to women who were receiving placebo, the cancer does not return. a surprise action by a panel of so that they too may benefit from the However, tamoxifen is only INexperts, a major international treatment,” says Dr. Goss. “This is the effective for about five years, clinical trial conceived and led by Dr. Paul first time we have proof of an effective Goss involving 5,187 women across treatment after tamoxifen that will keep leaving the survivors with nine countries was recently halted early cancer at bay in women who are at no effective therapies to follow. because the results were so astoundingly substantial ongoing risk of suffering positive. a relapse.” The trial was conducted under the The study showed letrozole to be auspices of the National Cancer Institute more effective than chemotherapy at of Canada’s Clinical Trials Group, the US preventing the recurrence of breast cancer. NCI and the Breast International Group “This finding will change the way breast in Europe. cancer is treated worldwide, and it offers The study, reported as an expedited significant new hope to women,” says on-line publication, showed that a new Dr. Goss. drug (letrozole), given after a round of N Engl J Med. 2003 treatment with tamoxifen, cut the risk of Nov 6; 349(19): 1793-802.
18 RESEARCH REPORT 2004 BREAKTHROUGHS
Head and Neck Cancer: New Nasopharyngeal cancer affects Therapy Delivers Killer Genes predominantly a young population, and FasL and Bims can both trigger current methods of control have a five-year cellular apoptosis, or cell ew research from a large team of UHN survival rate of only 70%. death–an effect that is useful Ninvestigators may bring us one step Exploiting the ability of genes such as in treating cancer cells closer to gene therapy for a type of cancer FasL or Bims to cause these cancer cells that affects people with Southeast Asian or to commit suicide, the team has modified Mediterranean backgrounds. these genes to make them safer by target- A team led by Drs. Fei-Fei Liu, Jeff ing their expression only in the cancer Medin, Peter Neligan, Pat Gullane, Brian cells, and then delivered them by direct O'Sullivan, Ralph Gilbert, Chris Richardson injections into tumours in mice. These and Wen-Chen Yeh, postdoctoral fellow genes stopped the growth of tumours Dr. Jian-Hua Li and graduate student Ken without noticeable toxicity, implying that Yip have developed a new way of making this strategy may be very promising for nasopharyngeal cancer cells more future development of treatments for Mol Ther. 2003 Dec; 8(6):964-73. vulnerable to radiation. human patients. Mol Ther. 2004 Sept; 10(3):533-544.
UNIVERSITY HEALTH NETWORK 19 BREAKTHROUGHS
Breast Cancer: Effects of enced more fatigue and menopausal Breast cancer survivors Chemotherapy Revealed symptoms than did healthy women. sometimes report symptoms Although the results of these studies of chemo-fog, a cognitive Ian Tannock and his can be used to advise patients about impairment that is a real DR. colleagues recently the adverse effects of chemotherapy, Dr. Tannock stresses that women issue for quality of life published a study showing that breast cancer patients receiving chemotherapy shouldn’t stop using chemotherapy to during recovery. scored more poorly on tests of memory treat their cancer. and language than did healthy women. “The negative side effects of Many breast cancer survivors report chemotherapy certainly don’t outweigh memory difficulties and being unable to the benefits. We are currently working to concentrate. The study, which is a follow- identify strategies that will ease these side up of Dr. Tannock’s 2000 study of the effects, and hopefully improve quality of same phenomenon, also showed that life for these women,” he says. the women receiving chemotherapy experi- J Clin Oncol. 2003 Nov 15;21(22):4175-83.
Genetics of Cancer: Missing “This finding was surprising because Holliday Junctions are structures Gene an Early Cancer Alert everyone had thought that this protein was allowing DNA to recombine required for the processing of DNA struc- and “cross-over”—generating team of OCI/PMH scientists tures called ’ Holliday Junctions’ that form the genetic diversity that Astunned the cancer research world during DNA repair. Our work disproves this is one of the keystones of the in June, 2004, with their announcement theory, and reveals an important function evolutionary process. that a protein discovered in yeast is a for Mus81 as a tumour suppressor,” powerful tumour suppressor. explains Dr. Hakem. Drs. Razq Hakem, Rama Khokha The next step is to determine whether and postdoctoral fellows Peter McPherson cancer patients have a mutated form of the and Bénédicte Lemmers showed that protein. “If this is shown to be true in a loss of one or both copies of the Mus81 humans, we will have a way of screening gene led to the development of lymphomas for people at risk,” he says. and other cancers in mice. Science. 2004 Jun 18;304(5678):1822-26.
Prostate Cancer: cause of cancer deaths in men, and PTEN is a tumour suppressor Loss of PTEN Implicated there is currently no known single cause gene that is essential for normal of its initiation,” says Dr. Chapman. cell growth and has been key cancer gene is critical for the “Our finding is the first to show that implicated in over 50% of all Adevelopment of prostate cancer, PTEN is critical for suppressing tumour types of human tumours. says a recent report authored by Drs. Tak development in the prostate. In the future Mak, Vuk Stambolic, Ming-Sound Tsao, we may be able to target preventive and William Chapman and student measures towards restoring this gene, Stephanie Backman. or reactivating it.” “Prostate cancer is the second leading PNAS. 2004 Feb 10;101(6):1725-30.
20 RESEARCH REPORT 2004 BREAKTHROUGHS
Photodynamic Therapy: Niedre took an approach never How Much is Enough? taken before. Photodynamic therapy is a new “Rather than measuring the amount treatment being used to treat ew research from the lab of Dr. Brian of PDT administered to the cancer cells, some types of esophageal and NWilson may help solve the problem of we measured the concentration of toxic lung cancers. how to dose photodynamic therapy (PDT), molecules produced,” Dr. Wilson explains. an emerging treatment for cancer. “We found that the number of cancer cells PDT is based on a drug that is activated that were destroyed was proportional to by light. After application, the drug zeroes the concentration of toxic molecules pro- in on cancer cells, accumulating in large duced, a finding that suggests that this concentrations. When activated by laser method could be used to measure PDT.’’ light, the drug produces toxic molecules The group plans further studies to test that destroy the cancer cells. the feasibility of using this non-invasive To determine exactly how much PDT technique to optimize PDT treatments is needed for effective treatment, in a clinical setting. Dr. Wilson and graduate student Mark Cancer Res. 2003 Nov 15; 63(22):7986-94.
Lymphoma: New Study lymphoid tissue (MALT) lymphoma. Confirms Treatment Choice Associated with various organs in the Radiation therapy is often in MALT Lymphoma body, including stomach, tissues surrounding used to treat localized cancers the eye, salivary glands and thyroid glands, at specific sites; chemotherapy mphasizing Princess Margaret this type of cancer is slow growing and not is often the treatment of EHospital’s leading role in cancer treat- prone to metastasis, indicating that it may be choice for cancers which have ment advances, a team of radiation oncolo- an excellent candidate for radiation therapy. metastasized, or dispersed. gists and radiation physicists led by The team studied responses of 85 Dr. Richard Tsang and including Drs. Mary patients to radiation therapy, and deter- Gospodarowicz, Woodrow Wells, mined that 84 of these patients had Alexander Sun, Michael Crump, David responded “extremely well” to moderate- Hodgson and Bruce Patterson and statisti- dose radiation therapy, showing that cian Melania Pintile has studied optimal radiation therapy is an excellent choice treatment strategies for a puzzling cancer for controlling this disease. called localized mucosa-associated J Clin Oncol. 2003 Nov 15;21(22):4157-64.
UNIVERSITY HEALTH NETWORK 21 BREAKTHROUGHS
Breakthroughs Toronto General Research Institute
AIDS: New Study Shows virals showed decreased amounts AIDS and malaria are twin Complexity of Treatment of CD36, a protein that is crucial for public health scourges of Response macrophages to eliminate red blood African countries. It is estimated cells infected with the malaria-causing that 22M Africans are infected or those co-infected with both Plasmodium parasite. The loss of CD36 with HIV and at least 500M FAIDS and malaria, the effect(s) caused a 50-60% reduction in the number of parasitised red blood cells that were have malaria. of antiretroviral drugs for the treatment of HIV on the clinical course of malaria purged from the blood, as part of the are unknown. New research by Dr. Kevin body’s protective immune response. Kain and postdoctoral fellow Lena This study calls attention to the Serghides has now shown that ritonavir potential for antiretroviral drugs to worsen and saquinavir—two antiretroviral drugs malaria, which in turn could worsen HIV commonly used to treat HIV—impair the disease progression and transmission, immune response to malaria. a potentially serious public health issue. Immune cells treated with the antiretro- Lancet. 2003 Sep 27;362(9389)1039-41.
22 RESEARCH REPORT 2004 BREAKTHROUGHS
SARS: UHN Develops showed faster improvement of their disease World’s First Treatment based on their lung X-rays, and they The World Health Organization required less oxygen than did comparable has adopted Dr. Fish’s new new treatment devised by Dr. Eleanor patients during the first phase of the out- treatment as the first standard AFish and based on antiviral proteins break (who did not receive interferon). treatment for this baffling called interferons has shown great “Although our findings are still disease. promise against SARS in preliminary tests. preliminary, they are extremely Interferons are produced by the immune encouraging. A global strategy for system to fight viral infections. SARS preparedness is being developed, During Toronto’s second SARS and it includes further examination outbreak, the new treatment was admin- of the potential therapeutic benefit istered to 19 patients with the help of Dr. of early treatment with interferon,” Mona Loutfy at North York General says Dr. Fish. Hospital. Only the four most critically ill The study also involved UHN died—suggesting that early treatment may researchers Drs. Kathy Siminovitch, be the key to its effectiveness. Kevin Kain and Gary Levy. Patients who received interferon JAMA. 2003 Dec 24;290(24):3222-8.
Lung Transplant: New is the transplant recipient’s own T cells Treatments on the Horizon that mediate reperfusion injury following According to the International for Transplant Patients transplant, a finding that has implications Society for Heart and Lung for how doctors might prevent and treat Transplantation, there are ecent findings from the labs of this type of injury. more than 1600 lung transplants RDrs. Shaf Keshavjee, Li Zhang, and J Immunol. 2003 Nov 15; performed each year around Tom Waddell have important implications 171 (10):4995-5002. the world. Reperfusion injury for preventing reperfusion injury—a is a common side effect involving severe side effect that can develop after an immune reaction between transplantation. Based on the knowledge that the the organ and its recipient. immune system’s T cells are involved in mediating this injury, the research team performed lung transplants on two groups of animals: those with their T cells intact, and those missing their T cells. Following transplant, it was clear that the mice with T cells had fared worse—their new lungs didn’t function as well, and there was evi- dence that the T cells were preparing to launch an attack on the transplanted lungs. These findings provide evidence that it
UNIVERSITY HEALTH NETWORK 23 BREAKTHROUGHS
Arthritis: Balancing Treatment of osteoarthritis, and celecoxib for the Arthritis costs the Canadian Costs with Benefits treatment of rheumatoid arthritis. Using healthcare system $4.4B a variety of assessment tools including annually, representing more the year 2026, it is estimated mathematical modeling techniques and than one quarter the total cost BYthat more than 6M Canadians Canadian databases, the team found that of musculoskeletal diseases. will have arthritis. To examine the sky- both drugs are economically attractive, rocketing costs associated with this dis- but only for elderly and “high risk” patients. ease, Dr. Andreas Maetzel—a specialist Thus, the message for physicians is clear: in the field of pharmacoeconomics— exercise discretion when prescribing these assesses the benefits of arthritis medications. medications, since the benefits may not Recently, two of the drugs under justify the costs in all patients. scrutiny were rofecoxib for the treatment Arthritis Rheum. 2003 Jun 15;49(3):283-92.
Cholesterol Levels: Obesity Using an animal model, the team found Heart disease, obesity, and Physical Inactivity Quell that HL eliminated the good cholesterol and diabetes: all are conditions Good Cholesterol from the body at a faster rate in the pres- associated with high levels of fats ence of elevated triglycerides—not the (triglycerides) in the blood and an aging population concerned with case in animals whose good cholesterol low levels of HDL cholesterol, INpreserving good circulatory health, was not enriched with triglycerides. a question that continues to plague “This suggests that high levels of fats in or “good” cholesterol. researchers is how do individuals lose the blood change the structure of the good HDL, or “good” cholesterol. cholesterol molecules, making them easier A study published by Dr. Gary Lewis and for HL to target and destroy—an important his team suggests that the answer may lie finding for controlling the harmful effects of in the interaction between triglycerides and fat in the diet,” says Dr. Lewis. the liver enzyme hepatic lipase (HL). Circulation. 2003 Jun 24;107(24):3066-72.
Leukemia: Targeting “Hidden” stem cells. Some LSCs are fast acting, Stem cells are powerful progenitor Cells for Successful Treatment while others can lie dormant for a long time cells. They are the “mother cells” before they become reactivated. that give rise to many different ew research by Dr. John Dick, “Our research suggests that leukemia types of “offspring” during growth Ngraduate student Kristin Hope, and recurs because chemotherapy isn’t and maintain the body as it ages. research associate Liqing Jin may help designed to target these dormant cells,” explain why 60-90% of leukemia patients says Dr. Dick. “Now that we know they’re suffer a recurrence following treatment. there, we need to figure out how to Using his pioneering method of studying eliminate them.” human stem cells, Dr. Dick and his team Dr. Dick predicts that similar cancer learned that there are many different types stem cells will be found for solid tumours, of leukemia stem cells (LSC), just as there such as breast cancer. are different types of regular, healthy blood Nat Immunol. Jul 5(7):738-43.
24 RESEARCH REPORT 2004 BREAKTHROUGHS
Lymphoma: Special cells attack the cancer, resulting in cancer T Cells May Improve regression. The current challenge is to Despite the fact that hematopoietic Treatment Success trigger the beneficial effects of the graft- stem cell transplants are widely versus-lymphoma phenomenon without used to treat lymphoma, graft- recent finding by a UHN investigator exposing the transplant recipient to an versus-host disease remains a Amay overcome a major hurdle in the increased risk of graft-versus-host disease. barrier to successful treatment. A team led by Dr. Li Zhang and gradu- development of immune-based therapies New immune-based therapies for cancer. ate student Kevin Young has now identified must overcome this risk. Bone marrow transplants are a common a special type of immune T cell, the DN T and successful treatment for cancer. cell, which can trigger the healing graft- However, a battlefield can potentially versus-lymphoma effects without causing develop as donor and recipient immune graft-versus-host disease. In a mouse cells wage war in the recipient. One type model, these DN T cells can directly kill of battle is “graft-versus-host disease”, lymphoma cells in vitro and prevent growth in which immune cells from a cell donor of the cancer. Thus the DN T cells may attack the recipient’s tissues, leading to offer a new treatment approach for cellular serious disease. Another type of battle is therapy of cancer. “graft-versus-lymphoma”, in which donor Cancer Res. 2003 Nov 15;63(22):8014-21.
Heart Failure: Protein ET-1 was full of immune cells,” explains Lures Immune Cells, Dr. Husain. “Since there was no real Endothelins are molecules Damaging Heart infection, the chemicals released by the that exert powerful control immune cells were damaging the heart, over the activities of our blood igh levels of the endothelin ET-1 in causing heart failure.” vessels. They play a role in Hthe heart lead to an increased risk of When the researchers treated these hypertension and other mice with drugs to block ET-1, they were heart failure, and the findings of a recent circulatory illnesses. study by Drs. Mansoor Husain and Avrum able to reduce the incidence of heart Gotlieb may tell us why. failure, proving that ET-1 was responsible Drs. Husain and Gotlieb compared for luring the immune cells to the heart. heart function in normal mice to heart func- The research points to a potential new tion in mice with high levels of ET-1. “The strategy for treating this condition. heart tissue of mice with high amounts of Circulation. 2004 Jan 20;109(2):255-61.
UNIVERSITY HEALTH NETWORK 25 BREAKTHROUGHS
Breakthroughs Toronto Western Research Institute
Molecular complicated than once thought. Controlling neurotransmitters Complexes Control Using state-of-the-art imaging technology, and their receptors is one Brain Function the research team found that the many activity of successful anti- proteins involved in releasing these depressants, anti-anxiety he cells of our nervous system chemicals—once thought to be separate drugs, drugs for high blood Tcommunicate with each other by from one another—are actually part of sending messages via chemicals called a single complex. pressure and heart disease, neurotransmitters. The release of these “Our research shows that the point of and nerve toxins including chemicals, though, requires several steps transmitter release contains highly evolved, snake and spider venom. and involves several proteins, and new miniscule molecular machines designed research by Dr. Elise Stanley and post- to transfer information between nerve cells doctoral fellows Qi Li and Anthony Lau under very tight control,” says Dr. Stanley. reveals that this process is far more J Neurosci. 2004 Apr 21;24(16):4070-81.
26 RESEARCH REPORT 2004 BREAKTHROUGHS
Childhood Cancer: Dr. Bremner found that some retinal Clue May Help Understand cells exhibit abnormal survival patterns— Retinoblastoma is the most Cancer Development patterns that are the hallmark of common childhood eye cancer. cancer cells. It can run in families or occur eatured as the cover story in the Says Dr. Bremner, “These cells may “sporadically” (without previous FJune issue of Cancer Cell, new be partially cancer-like to begin with. They family history). research by Dr. Rod Bremner and postdoc- may explain why retinoblastoma, as well toral fellows Danian Chen, Izhar Livne-bar as other childhood cancers, develop and Mahima Agochiya will lead to the in fewer steps than typical adult cancers. development of new treatments for It may also help us develop drugs that retinoblastoma, the most common eye interfere with the cellular development cancer in children. of cancers of many types.” Using mice that have retinoblastoma, Cancer Cell. 2004 Jun;5(6):539-551.
lnternal Clock: Tick-Tock Dr. Wan’s research shows that proteins of the Body Clock called GABAA receptors—long believed The body clock is involved Under Tight Control to be the principal clock regulators—are in insomnia, jet lag, response actually controlled by another protein to shift work and other rhythmic esearch by neuroscientist called CKI ∋ -CKIδ . functions and dysfunctions. RDr. Qi Wan provides new clues “Our research provides evidence regarding how our body’s internal clock of an intracellular mechanism for regulat- keeps such good time. ing synchronization of our body’s clock,” Our internal clock is made up of explains Dr. Wan. “It is relevant for the numerous “clock cells” that all work future development of treatments for together to control the timing of rhythmic people with health problems associated functions such as sleeping, waking, and with insomnia, shift work, and jet lag.” digestion, to name a few. Nat Neurosci. 2004 May;7(5):489-90.
UNIVERSITY HEALTH NETWORK 27 BREAKTHROUGHS
Lupus and Heart that women with SLE had higher levels Systemic lupus erythematosus, Disease: Risk Greater of fat molecules in their blood, including commonly called lupus, in Women With SLE triglycerides (the major form of fat) and is an autoimmune disease VLDL cholesterol (the “bad” cholesterol), affecting primarily women. the first large-scale study of its kind, which may be related to their basic disease INDrs. Dafna Gladman and Murray process or its therapy. Urowitz and TGRI/TGH’s Dr. George “Problems related to lipid metabolism Steiner looked for risk factors for coronary are characteristic of SLE,” explains artery disease in women with systemic Dr. Gladman, “and further studies are lupus erythematosus (SLE). Women needed to understand exactly how with SLE are known to have a greater this contributes to the increased risk risk for heart disease than other women. of heart disease in this high-risk patient The researchers compared the group. Although many patients can number of heart disease risk factors reduce their risk using screening and in women with and without SLE, and found intervention procedures, more research that based on classic heart disease risk is needed to learn how to accurately factors, the 10-year risk of heart attack was predict the risk of heart disease in the same in both groups of women. these patients.” However, the researchers did find Arthritis Rheum. 2003 Nov; 48(11):3159-67.
28 RESEARCH REPORT 2004 BREAKTHROUGHS
Hepatitis: Body Weight, had been effective. Dosing Closely Related The results showed that the therapy New research from a UHN was less effective in patients with a high group is making the medical new study by Drs. Jenny Heathcote body fat content (BMI>30) than in patients community re-examine the Aand Brian Bressler and TGRI/TGH’s with a BMI of less than 30. “This research relationship between body Dr. George Tomlinson shows that a shows how important it is to maintain a weight and drug efficacy. person’s body mass index (BMI)—a meas- healthy body weight,” says Dr. Heathcote, urement that describes a person’s weight “and we are currently investigating how relative to their height—may be a risk weight-based dosing may optimize treat- factor for determining their degree of ment success.” responsiveness to antiviral treatment for This research has spurred the FDA hepatitis C infection. to request that pharmaceutical companies A total of 253 hepatitis C patients who make therapies for hepatitis C were treated with antiviral therapies conduct further tests to examine the between 1989 and 2000. At six months effect of body weight on drug efficacy. post-therapy, their conditions were Hepatology. 2003 Sep;38(3):639-44. assessed to determine if the medications
Stroke: Main Source of Brain Damage Identified Much of the damage in the brain associated with stroke occurs xciting new research conducted hours and days after the initial Eby a team of researchers led by incident—leaving a window Dr. Michael Tymianski and colleague of time for preventive treatment. Dr. John MacDonald has provided a better understanding of how stroke causes brain damage. Reported in Cell, the research shows that when brain cells are deprived of oxygen and nutrients—as in a stroke— an ion channel on the surface of brain cells (called TRMP7) is activated. This releases toxic molecules, which then kill other, healthy brain cells in the vicinity. “Now that we know that TRMP7 is the culprit, we can focus on developing medications that will prevent these consequences and improve patient outcome,” says Dr. Tymianski. Cell. 2003 Dec 26; 115(7):863-877.
UNIVERSITY HEALTH NETWORK 29 FUNDING
Research Funding Revenues
ll figures represent fiscal year UHN Research Core Funding Total 2003/04 and include Ontario ($1,000s) A Cancer Institute (Princess Princess Margaret Hospital Foundation 14,500 Toronto General & Western Hospital Foundation 4,000 Margaret Hospital); Toronto General Arthritis & Autoimmunity Research Centre Foundation 1,500 Research Institute (Toronto General Recoveries 5,859 Hospital) and Toronto Western Research Investment Income 3,859 Ministry of Health & Long Term Care 2,816 Institute (Toronto Western Hospital). Other 7,835 These figures have been provided by UHN Research Financial Services and Total External Funding Awarded by Purpose of Funding ($1000’s) Research Grant and Contract Services. Operating Grants 75,261
Clinical Studies 11,786
Corporate Contracts 6,667
Infrastructure/Maintenance Awards 7,318
Career/Traineeship Awards 7,503
Other 7,072
Total 115,607
Major Sources of External Funding Total ($1000s) Canadian Institutes of Health Research 20,542 National Cancer Institute of Canada 9,886 Ontario R & D Challenge Fund 6,256 National Institutes of Health (U.S.) 6,234 Ontario Innovation Trust 6,198 Ontario Cancer Research Network 6,054 Heart and Stroke Foundations 4,438 Canada Foundation for Innovation 3,624
30 RESEARCH REPORT 2004 FUNDING
Research Funding External Agencies
Abbott Laboratories Radiation Oncologists F.Hoffman-La Roche Ltd (Switzerland) Medical Oncology Drug Investigation RIKEN Brain Science Institute (Japan) Achillion Pharmaceutical Canadian Breast Cancer Foundation Ferx Incorporated Medtronic (US) Roche Actelion Pharmaceuticals Canadian Breast Cancer Foundation for Lung Cancer Medtronic Neurological (US) Roche Organ Transplantation Agouron Pharma Research Initiative Fournier (France) Medtronic of Canada Research Foundation (Switzerland) Alcon Research Canadian Cancer Etiology Fragile X Research Foundation Merck Frosst Canada & Co. Roferon Allergan Sales Research Network of Canada MERIX Bioscience (US) SAIC Frederick (US) Alteon Canadian Cancer Society (Ontario) Fujisawa Canada Michael J. Fox Foundation for Sandoz Canada Alzheimer Society of Canada Canadian Coordinating Office for Fujisawa Healthcare Parkinson’s Research (US) Sanofi-Synthelabo Canada Alzheimer’s Disease and Related Health Technology Assessment Genome Quebec Michael Smith Foundation for Schering Canada Disorders Association Canadian Cystic Fibrosis Foundation GENTA Incorporated Health Research Searle Canada AmCyte Canadian Dermatology Foundation Geoffrey H. Wood Foundation Miikana Therapeutics Sepsis American Association for Canadian Diabetes Association Giliad Sciences Millenium Pharmaceuticals (US) Serono Thoracic Surgery Canadian Foundation for AIDS Research Glaxo Ministry of Health & Long Term Care Servier Canada American Association of Neurological Canadian Health Services Research GlaxoSmithKline Molecular Templates Siemens Medical Solutions Surgeons and Congress of Foundation GlycoDesign Multiple Myeloma Research Foundation Social Sciences and Humanities Neurological Surgeons Canadian Institutes of Health Research Government of Canada-Canadian Multiple Sclerosis Society of Canada Research Council of Canada American College of Surgeons Canadian Liver Foundation Space Agency National Cancer Institute of Canada Solutions By Sequence Oncology Group Canadian Lung Association Guidant Europe National Institutes of Health STEBA BEHEER (Netherlands) American Digestive Health Foundation Canadian Prostate Centre Health Canada National Organization for Rare Disorders Stryker Biotech American Foundation for AIDS Canadian Society of Hospital Heart and Stroke Foundation National Sanitarium Association SuperGen Research Pharmacists Hemosol National Surgical Adjuvant Breast and Surgical Infection Society American Society of Clinical Oncology Canadian Urologic Oncology Group Hoffman-La Roche Bowel Project Susan G. Komen Breast Cancer American Society of Echocardiography Cancer Care Ontario Howard Hughes Medical Institute (US) Natural Sciences and Engineering Foundation American Society of Hematology Cancer Research Institute IBM Research Council Synbiotics American Society of Interventional & Cancer Research Society Idenix Pharmaceuticals Networks of Centres of Excellence T Cell Sciences Therapeutic Neurology Cangene Corporation Canadian Ilex Oncology Program Taylor & Frances Group Publishing Amersham Chiropractic Protective Association & Immunex Corporation Neurologix Thoracic Surgery Foundation for Amgen National Chiropractic Mutual Intermune North American Spine Society Research and Education AO-ASIF Research Foundation Insurance Company International Association for the Northwestern University Tiffin Trust Fund Arius Research Celgene Corporation Study of Pain Novartis Pharmaceuticals Canada Toronto Medical Laboratories Arthritis Community Research & Cell Therapeutics International Association for the Novirio Pharmaceuticals Transkaryotic Therapies Evaluation Unit Cervical Spine Research Society Study of the Liver Novopharm Biotech Transplantation Technologies Arthritis Society Change Foundation International Society for Heart & Lung Nyocemed Amersham Tri-Hospital MR Centre Associated Medical Services Ontario Ministry of Health Transplantation Ontario Cancer Research Network Bloorview Epilepsy Research Incorporated CLP Research (Switzerland) International Union Against Cancer Ontario Consortium for Image Guided Premier’s Research Excellence Awards Astra Pharma Cook (Canada) International Union of Biochemistry Therapy & Surgery Canada Research Chairs Program AstraZeneca Corgentech and Molecular Biology Ontario Genomics Institute Health Evidence Application and Aventis Pasteur Corvita Canada IVAX Research Ontario HIV Treatment Network Linkage Network Banting and Best Diabetes Centre Covance Janssen Pharmaceuticals Ontario Hospital Association US Army Medical Research Bausch and Lomb Crohn’s and Colitis Foundation Janssen-Ortho Ontario Innovation Trust Acquisition Activity Baxter Healthcare Corporation of Canada Johnson & Johnson Pharmaceutical Ontario Lupus Association University of Toronto Bayer Cyanamid Research & Development Ontario Mental Health Foundation University Renal Research & Beckman Coulter Defense and Civil Institute of Journal of Medical Internet Research Ontario Neurotrauma Foundation Education Association Berlex Laboratories Environmental Medicine Jupiter Bioscience (India) Ontario R & D Challenge Fund Argonne National Research Lab Biochem Therapeutic Delex Therapeutics Juvenile Diabetes Foundation Ortho Biotech Varian Biosynergy BioMedicines Den Haag Trust International Otsuka Varian Medical Systems, Inc Bloorview Epilepsy Research Department of National Defense Kidney Foundation of Canada Pfizer Canada Vasogen Boehringer Ingelheim Dystonia Medical Research Foundation Knoll Pharmaceutical Company Pharmacia Vicuron Pharmaceuticals Boston Scientific Corporation ECHO Research Kourion Therapeutics (Germany) PharmaResearch Wegener’s Granulomatosis Association Brahms Diagnostica Edwards Lifesciences La Jolla Pharmaceutical Company Physicians Services Incorporated Workplace Safety and Insurance Board Breast Cancer Society of Canada EISAI Medical Research Leukemia & Lymphoma Society Foundation Wyeth-Ayerst Canada Bristol-Myers Squibb Pharmaceutical Elan Pharmaceutical Leukemia Research Foundation Picker International Canada York Medical Research Institute Elekta Oncology Systems (UK) Leukemia Research Fund of Canada Possis Medical Zarix Broncus Technologies Eli Lilly Lifeline Foundation Proctor & Gamble Zeneca Pharma C.R. Younger Foundation Endpoint Research Lupus Canada Prostate Cancer Research Foundation Canada Foundation for Innovation Epilepsy Canada Lupus Clinical Trials Consortium of Canada Canadian Anesthesiologists Society Erbe USA Incorp Mallinkrodt Medical Purdue Frederick Canadian Association of Eye Research Institute of Canada Med Innova Partners Rhone Poulenc
UNIVERSITY HEALTH NETWORK 31 COMMITTEES
Committees UHN Research
Biosafety Committee BOARD B Kittie Tomson Erik Yeo Jim Brunton (Chair) Ronald Heslegrave (Chair) John Waldron Bruce Youngson Fei-Fei Liu Piri Babos Woody Wells Yeni Yucel Ian McDermott David Barth Jeff Medin Paul Daly Human Tissue Animal Care Joan Wither Wilfred Cassar-Demajo Committee Committee Patricia Clark (ex officio) Ronald Heslegrave (Chair) ONTARIO CANCER Radionuclide Safety Carolyn Gillis Michele Henry INSTITUTE Committee Jin Huh Richard Hill Rama Khokha (Chair) Ian McDermott (Co-Chair) Margaret Hume Michael Johnston Alejandro Ceccarelli Frank Tourneur (Co-Chair) William Hutchison Fei-Fei Liu Richard Hill Neil Amos Fred Koning Patrick Shannon Robert Lopez Sam Benchimol Patricia Lombard Patricia Shaw Badru Moloo Rod Bremner Roger McIntyre Ming-Sound Tsao Beryl Nash Ron Burke Vaska Micevski Mary Jane Salpeter Suzanne Plyte Eleanor Fish Katrine Milner Christine Quarrington Aaron Hendler Gregory Pond AD HOC MEMBERS David Rose Scott Jarrett Dawn Virag Sylvia Asa Sarah Sabatinos Shawn Ramdhany Jean Wong Denis Bailey Barbara Wand Scott Boerner Richard Wells Research BOARD C - ONCOLOGY Robert Bristow Wen-Chen Yeh Ethics Board Ronald Heslegrave (Chair) Jagdish Butany BOARD A Michael Crump (Vice Chair) William Chapman Equipment Ronald Heslegrave (Chair) Nancy Bestic Michael Crump Committee Alan Barolet Carol Ann Buckley Shereen Ezzat ONTARIO CANCER Theodore Brown Patricia Clark (ex officio) Anthony Fyles INSTITUTE Derek Cathcart Paola Cubillos Brenda Gallie Richard Hill (Chair) Lori DiMonte Laura Dawson Ralph Gilbert Dwayne Barber Keyvan Karkouti Pam Degendorfer Abjihit Guha Sam Benchimol Robert Richardson Heidi Gotthardt Maha Guindi Ian McDermott Katherine Roposa Michele Henry David Hedley Gil Privé Ruxandra Pinto Natasha Leighl Michael Johnston Malcolm Smith Robert Rueter Wey Leong Rita Kandel Jim Woodgett Heather Sampson Michael McLean Naomi Miller Ron Seto Jane Nagai Mark Minden Space Committee Katherine Tsang Tony Panzarella Joan Murphy ONTARIO CANCER Dawn Virag (ex officio) Larissa Potanina Brian O'Sullivan INSTITUTE (AD HOC) Diane Watson Michael Reedjik Bayardo Perez-Ordonez Sam Benchimol (Chair) Linda Wright Heather Sampson Patrick Shannon Norman Boyd Krystyna Sherman Joan Sweet Brenda Gallie Donald Short Ming-Sound Tsao Emil Pai
32 RESEARCH REPORT 2004 COMMITTEES
Christopher J. Paige Jennifer Hornby Ren-Ke Li Stuart Berger Brian Wilson Jane Negai Badru Moloo Elizabeth Badley Jim Woodgett Lori Ann Rayburn Jeff Tong Simon Carette Huberta Selormey Peter Ruderman Michael Fehlings Clinical Studies Eldad Zacksenhaus Andres Lozano Resource Centre Cancer Registry Elise Stanley Executive and Data Access Equipment Martin Steinbach PMH/OCI Committee Committee Robert Bell (Chair) Jim Brierley (Co-Chair) TORONTO GENERAL Shared Equipment Armand Keating Darlene Dale (Co-Chair) RESEARCH INSTITUTE Committee Mary Gospodarowicz Alexandra Easson Eleanor Fish (Chair) TORONTO WESTERN Jon Irish Vikas Gupta Reg Gorczynski RESEARCH INSTITUTE Gary Rodin Ozgur Huner Mansoor Husain Martin Steinbach (Chair) Michael Milosevic Jon Irish Kevin Kain Shelley Belford Malcolm Moore Brian O’Sullivan Andras Kapus Rod Bremner Neil Fleshner Krista Montgomery Ren-Ke Li Jan Jongstra Gerald Devins Tony Panzarella Mingyao Liu Ian McDermott Narinder Paul Ian McDermott Linda Mills Sylvia Asa Data Safety Kelly Macdonald Juliet Sheldon Lee Fairclough (CSRC) Monitoring Board Eldad Zacksenhaus Michael Tymianski Darlene Dale (Cancer Registry) PRINCESS MARGARET Li Zhang Tony Panzarella (Biostatistics) HOSPITAL Space Committee Jolie Ringash (Chair) Space Committee TORONTO WESTERN Clinical Research Mark Minden (Co-Chair) TORONTO GENERAL RESEARCH INSTITUTE Implementation Dale Brown RESEARCH INSTITUTE Chris Wallace (Interim Chair) Committee Paola Cubillos-Rizo Eleanor Fish (Chair) Jim Eubanks CLINICAL STUDIES Gina Lockwood Stuart Berger Paul Fortin RESOURCE CENTRE, Jennifer Petronis Claire Bombardier Ian McDermott PMH/OCI David Warr Myron Cybulsky Paola Cubillos-Rizo Dan Drucker Trainee Affairs Pam Degendorfer Animal Care Mansoor Husain Committee Darlene Dale Committee Ian McDermott TORONTO WESTERN Gerald Devins TORONTO GENERAL AND Keith Stewart RESEARCH INSTITUTE Lee Fairclough TORONTO WESTERN Christopher Wallace Vicki Gillman RESEARCH INSTITUTES Research Frances Skinner Karen Hersey Thomas Lindsay (Chair) Appointments Allison Guy Tony Panzarella Shelley Belford Committee Jillian Couto Susanna Sellman Lyssa Cheng TORONTO WESTERN Raquel Heskin Ron Seto Kathleen Cook RESEARCH INSTITUTE Janet Smith Hossam El-Behiery Christopher Wallace Sheila Webster Jim Eubanks (Acting Chair)
UNIVERSITY HEALTH NETWORK 33 SERVICES
Research Support Services at UHN
esearch Support Services pro- investigators in initiating, conducting, Research Facilities: Involves the man- vides a supportive collaborative managing and analyzing investigator-driven agement of office and lab space, reloca- R infrastructure for research across and industry-sponsored clinical research tions and renovations, core equipment and UHN’s institutes. Approximately 240 RSS general equipment, maintenance, and safety staff support UHN’s researchers, staff Research Business Development and trainees. Office: Commercializes research discov- Research Financial Services: eries that help investigate, treat and diag- Provides financial information and services Animal Resource Centre: Provides nose disease, to generate revenue for to investigators, research administration facilities, care and technical services for inventors and research reinvestment and sponsors related to research funding animal models used in research as well and disbursements as experimental design support and Research Communications and ethics review Proposal Development: Develops Research Information Systems: print and electronic communications in Provides researchers a full range of com- Grant and Contract Services: consultation with internal and external puting services from email and file storage Reviews clinical trial agreements, tracks stakeholders for various audiences to remote access and the power of high information regarding employees and processing clusters grants, and processes documents for Research Ethics Board: Oversees hiring new research staff research involving human subjects to Research Program Planning and ensure it meets scientific and ethical stan- Analysis: Provides analyses of research Clinical Studies Resource Centres dards to protect patients, investigators and activity and supports performance evalua- (PMH and TGH/TWH): Assists clinical the institution tion activities of research programs and departments
Sterilization, Sera and Media Services: Co-ordinates the purchase, cleaning and sterilization of laboratory glassware and the provision of tissue cul- ture and bacteriological media
Vice President’s Office: Provides strategic leadership for UHN Research in consultation with the Research Councils
Research Information Systems
34 RESEARCH REPORT 2004 RESEARCH ACTIVITY
Analysis of Research Activity at UHN
early every paper published Citation Data for Papers in a peer-reviewed journal Published by UHN Researchers 2001/03 N contains a list of citations: refer- ences to earlier papers which helped the 2001/03 Total Papers Citations Cites/Paper Papers in Top Papers* authors define and answer their current to Date Top Journals* research question. A paper which is influ- OCI 1040 9753 9.4 142 (14%) 283 (37%) ential in its field will be cited frequently by TGRI 1620 12243 7.6 157 (10%) 518 (32%) other authors over the months and years TWRI 1068 5524 5.2 49 (5%) 200 (19%) following its publication. UHN 3613** 24621 6.8 338 (9%) 930 (26%) Citation analysis is used by institutions around the world as one way of measuring **Where papers are collaborations between scientists at different UHN research institutes, papers are counted only once in the “UHN” total research productivity and success. UHN *“Top Journals” are those journals with an impact factor>10, and Research has over the past three years “Top Papers” are papers in the top 10% of cited papers begun collecting citation analysis information (as defined by the Institute for Scientific Information) to determine its usefulness as a method of Benchmarking to Peer Institutions, 2001/03 measuring scientific impact over time. Citation analysis uses computer data- Top Papers bases to search and count all references Cleveland Clinic 22% to a certain paper to determine its impact UHN 26% on a field. We can also do this for all Johns Hopkins 27% papers published by a scientist or group Massachusetts General Hospital 30% of scientists over a defined time period.
UNIVERSITY HEALTH NETWORK 35 CHAIRS
Endowed Chairs at UHN
uch of the research and Spinal Cord Research Epstein Chair (in Cell Dr. Bryce Taylor Tanenbaum/Brazilian Ball at UHN is made Dr. Ming Tsao Therapy & Transplantation) James Wallace McCutcheon Chair in Prostate Cancer M possible through M. Qasim Choksi Lung Cancer Dr. David Jaffray Chair in Surgery Research the generosity of donors, Chair in Translational Research The Orey and Mary Fidani (to be appointed) Dr. Andres Lozano who contribute to UHN’s Dr. Ori Rotstein Family Chair in Radiation Robert & Cheryl McEwen The R.R. Tasker Chair in work through the three Peter A. Crossgrove Chair in Physics Chair in Cardiac Stereotactic and Functional UHN Foundations and General Surgery Dr. John Trachtenberg Regenerative Medicine Neurosurgery their fund-raising efforts. Dr. Glenn Regehr The Fleck/Tanenbaum Chair Dr. Tirone David Dr. Frances Shepherd Among the most gener- Richard & Elizabeth Currie in Prostatic Diseases The Melanie Munk Chair The Scott Taylor Chair in ous of contributions is an Chair in Health Professions Dr. David McCready in Cardiovascular Surgery Lung Cancer Research endowed Chair, established Education Research Gattuso Chair in Breast Dr. Mark Minden (to be appointed) at a minimum level of $2M. Dr. James Rutka Surgical Oncology The Philip S. Orsino Chair Tyco Chair in Minimally The income from this endow- The Dan Family Chair in Dr. Malcolm Moore in Leukemia Research Invasive Surgery ment provides ongoing fund- Neurosurgery The K.Y. Ho Chair in Prostate Dr. John Parker Dr. Pat Gullane ing for the Chairholder. There (to be appointed) Cancer Research The Pharmacia Chair in The Robert E. Wharton Chair are currently 53 endowed Angelo & Lorenza DeGasperis Dr. Michael Baker Cardiovascular Research in Head & Neck Surgery Chairs established at UHN or Chair in Cardiovascular Charles H. Hollenberg Chair Dr. Allan Kaplan Dr. Peter Neligan held by UHN investigators. Surgery Research in Medicine at UHN Loretta Anne Rogers Chair in The Robert E. Wharton Chair in (to be appointed) Dr. Abhijit Guha Eating Disorders Reconstructive Plastic Surgery Dr. Jim Woodgett Alfredo & Teresa DeGasperis The Alan & Susan Hudson (to be appointed) U of T Chairs Held by The AMGEN Chair in Chair in the Surgical Chair in Neuro-Oncology Sandra Rotman Chair in UHN Appointed Staff Cancer Research Management of Heart Failure Dr. Michael Fehlings Health Care Management at Dr. Elise Stanley Dr. Brian O’Sullivan (to be appointed) The Krembil Chair in Neural University of Toronto and The Anne and Max The Bartley-Smith/Wharton Antonio & Helga DeGasperis Repair and Regeneration University Health Network Tanenbaum Chair in Chair in Radiation Oncology Chair in Clinical Trials and Dr. Catherine Zahn (to be appointed) Molecular Neurosciences Dr. Ian Tannock Outcomes Research The Krembil Family RBC Financial Group Dr. Chris Wallace The Daniel E. Bergsagel Dr. Fei-Fei Liu Chair in Neurology Chair in Cardiovascular The Fondation Baxter Chair in Medical Oncology Dr. Mariano Antonio Elia Dr. Norman Boyd Nursing Research and Alma Ricard Chair (to be appointed) Chair in Head and Neck The Lau Family Chair in Dr. Doris Howell (in Cerebrovascular BMO Financial Group Chair Cancer Research Breast Cancer Research RBC Financial Group Chair in Neurosurgery) in Health Professions Dr. Scott Beattie (to be appointed) Oncology Nursing Research Dr. Peter Liu Education Research The R. Fraser Elliott Chair Harold & Shirley Lederman Dr. Keith Stewart The Heart & Stroke Dr. Jeremy Squire in Cardiac Anaesthesia Chair in Palliative Care, The J. Gerald Scott/David G. Foundation Polo Chair in The JC Boileau Grant Chair Dr. Gregory Downey Psychosocial Oncology Whitmore Chair in Cardiovascular Research in Oncologic Pathology The R. Fraser Elliott Chair in Dr. Donna Stewart Haematology and Gene Dr. Anthony Lang Dr. Christopher Paige Transplantation Research The Lillian Love Chair in Therapy Research The Jack Clark Chair in The Ronald N. Buick Chair in Dr. K. Wayne Johnston Women’s Health Dr. Nizar Mohammed Parkinson’s Disease Research Cancer Research The R. Fraser Elliott Chair in (to be appointed) The Smith & Nephew Chair in Dr. Alex Jadad Dr. Charles Tator Vascular Surgery John and Gail MacNaughton Orthopaedic Surgery Research Rose Family Chair in The Robert Campeau Family Dr. Armand Keating Chair in Thoracic (to be appointed) Supportive Care – Palliative Foundation Chair in Brain The Gloria & Seymour Radiation Oncology The Joey and Toby Medicine
36 RESEARCH REPORT 2004 IRAB
International Research Advisory Board
Victor Ling, PhD (Chair) Vice-President, Research, at the BC Cancer Agency
Ferid Murad, MD, PhD Nobel Prize winner and Director of the Institute of Molecular Medicine at the University of Texas
Mark Musen, MD, PhD Head, Stanford Medical Informatics, Stanford University
Malcolm Pike, PhD Professor in the Department of Preventive Medicine, University of Southern California
The third IRAB meeting will take place November 2004.
UNIVERSITY HEALTH NETWORK 37 20 04 RESEARCH REPORT
Toronto General Research Institute Toronto General Hospital 150 Gerrard Street - 4G505 Toronto, Ontario Canada M5G 2C4 416.340.4800 ext. 6333 416.340.4417 (fax)
Toronto Western Research Institute Toronto Western Hospital 14th Floor Main Pavilion, Room 324 399 Bathurst Street Toronto, Ontario Canada M5T 2S8 416.603.5030 416.603.5745 (fax)
Ontario Cancer Institute Princess Margaret Hospital 7th Floor, Room 7-504 610 University Avenue Toronto, Ontario Canada M5G 2M9 416.946.2951 416.946.2287 (fax)
www.uhnresearch.ca